S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:BLFS

BioLife Solutions (BLFS) Stock Forecast, Price & News

$12.42
+1.26 (+11.29%)
(As of 05/13/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.42
$12.57
50-Day Range
$10.54
$24.61
52-Week Range
$10.40
$60.67
Volume
526,809 shs
Average Volume
519,823 shs
Market Capitalization
$526.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.01
30 days | 90 days | 365 days | Advanced Chart
Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BioLife Solutions logo

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Sales & Book Value

Annual Sales
$119.16 million
Book Value
$11.28 per share

Profitability

Net Income
$-7.64 million
Pretax Margin
-24.76%

Debt

Price-To-Earnings

Miscellaneous

Free Float
39,908,000
Market Cap
$526.73 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/09/2022
Today
5/15/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

347th out of 1,403 stocks

Electromedical Equipment Industry

7th out of 29 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

Is BioLife Solutions a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions
or view top-rated stocks.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for BioLife Solutions
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings results on Monday, May, 9th. The medical equipment provider reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.06. BioLife Solutions had a negative trailing twelve-month return on equity of 6.24% and a negative net margin of 10.35%. During the same quarter in the previous year, the company earned $0.01 earnings per share.
View BioLife Solutions' earnings history
.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $159.50 million-$171.00 million, compared to the consensus revenue estimate of $165.38 million.

What price target have analysts set for BLFS?

7 Wall Street analysts have issued 12 month price objectives for BioLife Solutions' stock. Their forecasts range from $30.00 to $65.00. On average, they expect BioLife Solutions' stock price to reach $44.50 in the next year. This suggests a possible upside of 258.3% from the stock's current price.
View analysts' price targets for BioLife Solutions
or view top-rated stocks among Wall Street analysts.

Who are BioLife Solutions' key executives?
BioLife Solutions' management team includes the following people:
What is Mike Rice's approval rating as BioLife Solutions' CEO?

5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.82%), Vanguard Group Inc. (5.23%), Geneva Capital Management LLC (3.46%), Palisade Capital Management LLC NJ (1.31%), TimesSquare Capital Management LLC (1.14%) and Russell Investments Group Ltd. (1.08%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Aby J Mathew, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends for BioLife Solutions
.

Which institutional investors are selling BioLife Solutions stock?

BLFS stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Russell Investments Group Ltd., Victory Capital Management Inc., Dimensional Fund Advisors LP, Palisade Capital Management LLC NJ, Geneva Capital Management LLC, JPMorgan Chase & Co., and Prudential Financial Inc.. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Andrew G Hinson, Greef Roderick De, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard, and Troy Wichterman.
View insider buying and selling activity for BioLife Solutions
or view top insider-selling stocks.

Which institutional investors are buying BioLife Solutions stock?

BLFS stock was purchased by a variety of institutional investors in the last quarter, including Barings LLC, Pier Capital LLC, Gagnon Securities LLC, Zweig DiMenna Associates LLC, BlackRock Inc., Vanguard Group Inc., Qube Research & Technologies Ltd, and RMB Capital Management LLC.
View insider buying and selling activity for BioLife Solutions
or or view top insider-buying stocks.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $12.42.

How much money does BioLife Solutions make?

BioLife Solutions has a market capitalization of $526.73 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7.64 million in net income (profit) each year or ($0.350010) on an earnings per share basis.

How many employees does BioLife Solutions have?

BioLife Solutions employs 432 workers across the globe.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is www.biolifesolutions.com.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at (425) 402-1400, via email at [email protected], or via fax at 425-402-1433.

This page was last updated on 5/15/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.